Information Provided By:
Fly News Breaks for February 5, 2016
VRTX
Feb 5, 2016 | 10:31 EDT
Leerink analyst Geoffrey Porges views the Complete Response Letter from the FDA declining the supplemental New Drug Application for Kalydeco as a minor setback for Vertex. Porges says that while approval for the mutation population was not a central part of his Vertex thesis, it was a driver of incremental revenue for Kalydeco in 2016 and 2017. He keeps an Outperform rating on the stock.
News For VRTX From the Last 2 Days
There are no results for your query VRTX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.